ArticleProceedings of the National Academy of Sciences of the United States of America2024
Lutetium texaphyrin: A photocatalyst that triggers pyroptosis via biomolecular photoredox catalysis.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 33 citations in OpenAlex.
- Preparation of ENBSe-based photoredox catalysts for ONature protocols · 2026Review
- NIR-II photothermal-driven pulsatile PTH release for osteoporotic bone repair.National science review · 2026Article
- Selenoxanthylium Salts─Organic Photocatalysts for Low-Energy Photoredox Catalysis.Journal of the American Chemical Society · 2026Article
- Irreversible NADH Cleavage by a Mitochondria-Targeted Metal-Free Photoredox Sensitizer with Activity in Cancer Cells.ACS medicinal chemistry letters · 2026Article
- Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Brightening New Horizons: Luminescent Transition Metal Complexes in Optical Imaging and Theranostic Applications.ACS central science · 2025Review
- Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities.Biomarker research · 2025Review
- Photon-triggered pyroptosis and ferroptosis dual-functional nanoplatform for cancer immunotherapy.Light, science & applications · 2025Article
- Trapped in Cells: A Selective Accumulation Approach for Type-I Photodynamic Ablation of Cancer Stem-like Cells.JACS Au · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Photon-controlled pyroptosis activation (PhotoPyro) is a promising technique for cancer immunotherapy due to its noninvasive nature, precise control, and ease of operation. Here, we report that biomolecular photoredox catalysis in cells might be an important mechanism underlying PhotoPyro. Our findings reveal that the photocatalyst lutetium texaphyrin (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.